Demonstrating product value is becoming more complex across therapeutic areas and impacting biotech, specialty and larger pharma alike. The key stakeholders involved in the ultimate success of a drug, and their evidence needs, continue to evolve as the marketplace transforms from volume- to value-based performance.
Coupled with the need for time and cost efficiency in clinical development, this drives a need for cross-functional convergence through process and organizational optimization. This must focus on stakeholder inclusiveness, systems value integration and agile evidence delivery.
Recommitting to strategic and operational basics with consistent and integrated processes will be vital to enabling cross-functional teams to efficiently deliver integrated asset development programs and get high value products to the patients who need them. In addition to improved process rigor, organizations should focus on fundamentals around culture, incentives, training and communication to consistently meet evolving health system evidence needs.
不断发展对综合资产价值演示的需求
随着全球医疗保健成本必威手机APP继续上升，卫生系统继续进行改革以控制这些成本，参与药物最终成功的主要利益相关者，其证据需求继续发展 - 要求公司接受基于价值的医疗保健以推动人口成果的改善并最大化创新回报。对生物制药的综合估值的需求与当今的肿瘤学更具刺激性，传统上以医学为中心的组织（如ASCO，MSKCC和NCCN）都要求肿瘤学有价值的证据。（有关相互依存的医疗趋势的含义的更多信息，请参阅IQVIA以前的出版物，对成果的价值。）必威手机APP
The pharmaceutical company’s mandate to collect the right evidence to demonstrate a medicine’s value to stakeholders has never been stronger, driving an evolution in Regulatory, Clinical, Market Access, Medical (including Health Economic Outcomes Research (HEOR)) and Commercial strategies in clinical development.
To align with this landscape shift and new market demands, some pharma companies have started to transform their business model from a transactional organization towards an integrated, outcomes-based approach. Evidence of this strategy can be seen across the biopharmaceutical industry under the rallying cry of selling outcomes. The systems view governing the market today warrants linking and synchronizing these components within companies to amplify health system performance. Evidence development, translation and demonstration requires a harmonized process.